Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Let The U.S. Drug-Coated Balloon Battle Begin

This article was originally published in The Gray Sheet

Executive Summary

Medtronic gained FDA approval for its drug-coated balloon for the peripheral artery, as expected, and it is now gunning to take share from first-to-market C.R. Bard with the help of impressive clinical data and a formidable Covidien peripheral vascular device sales force.

Advertisement

Related Content

Market Update: Growth And Opportunities In Peripheral Artery Disease
New Product Briefs
Drug-Coated Balloons Net Medicare Inpatient Bonus Payments
Medicare Advisors Lukewarm On Lower Extremity PAD Intervention Evidence
Medicare Coverage Advisors Will Consider Evidence For PAD Interventions
CMS Raises Concerns With New-Technology Payment Candidates
CMS Raises Questions About New-Technology Payment Candidates
Boston Sci, Bard Link Up To Contend With Medtronic In Drug-Coated Balloons
Drug-Coated Balloons Fuel Multibillion-Dollar Hopes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT033898

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel